Claire Houzard
Overview
Explore the profile of Claire Houzard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ceccaldi M, Jonveaux T, Verger A, Krolak-Salmon P, Houzard C, Godefroy O, et al.
Alzheimers Dement
. 2017 Nov;
14(3):293-305.
PMID: 29107051
Introduction: Although some studies have previously addressed the clinical impact of amyloid positron emission tomography (PET), none has specifically addressed its selective and hierarchical implementation in relation to cerebrospinal fluid...
2.
Moreau A, Giraudet A, Kryza D, Borson-Chazot F, Bournaud C, Mognetti T, et al.
Nucl Med Commun
. 2017 Jul;
38(9):771-779.
PMID: 28704339
Introduction: Many studies have reported the high performance of 6-fluorine-18-fluorodihydroxyphenilalanine (F-FDOPA) PET/CT in the diagnosis of pheochromocytomas but nobody seems to have investigated physiological and pathological adrenal glands from a...
3.
Guerin C, Pattou F, Brunaud L, Lifante J, Mirallie E, Haissaguerre M, et al.
J Clin Endocrinol Metab
. 2017 Apr;
102(7):2465-2472.
PMID: 28431167
Context: Few prospective studies have evaluated the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the characterization of adrenal masses. Objective: To assess the performance of 18F-FDG PET/CT...
4.
Moreau A, Giraudet A, Kryza D, Borson-Chazot F, Bournaud-Salinas C, Mognetti T, et al.
Clin Nucl Med
. 2017 Mar;
42(5):379-382.
PMID: 28319498
F-FDOPA is a well-established tool to explore pheochromocytomas. It tends to replace I-MIBG scan in metastatic pheochromocytomas, multiple endocrine neoplasia type 2-related tumors, succinate dehydrogenase [ubiquinone] iron-sulfur subunit-negative tumors, and...
5.
Vera P, Thureau S, Chaumet-Riffaud P, Modzelewski R, Bohn P, Vermandel M, et al.
J Nucl Med
. 2017 Mar;
58(7):1045-1053.
PMID: 28254869
See an invited perspective on this article on page 1043.This multicenter phase II study investigated a selective radiotherapy dose increase to tumor areas with significant F-misonidazole (F-FMISO) uptake in patients...
6.
Kepenekian L, Mognetti T, Lifante J, Giraudet A, Houzard C, Pinson S, et al.
Eur J Endocrinol
. 2016 Jul;
175(4):335-44.
PMID: 27450695
Objective: Pheochromocytoma (PHEO) may occur in 0.1-5.7% of patients presenting with a neurofibromatosis type 1 (NF1). Current recommendations are to explore only symptomatic patients. The objective of the study is...
7.
Vera P, Mezzani-Saillard S, Edet-Sanson A, Menard J, Modzelewski R, Thureau S, et al.
Eur J Nucl Med Mol Imaging
. 2014 Feb;
41(6):1057-65.
PMID: 24562641
Purpose: To assess prospectively the prognostic value of FDG PET/CT during curative-intent radiotherapy (RT) with or without concomitant chemotherapy in patients with non-small-cell lung cancer (NSCLC). Methods: Patients with histological...
8.
Thureau S, Chaumet-Riffaud P, Modzelewski R, Fernandez P, Tessonnier L, Vervueren L, et al.
J Nucl Med
. 2013 Aug;
54(9):1543-50.
PMID: 23918733
Unlabelled: As the preparation phase of a multicenter clinical trial using (18)F-fluoro-2-deoxy-d-glucose ((18)F-FDG), (18)F-fluoromisonidazole ((18)F-FMISO), and 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in non-small cell lung cancer (NSCLC) patients, we investigated whether 18 nuclear...
9.
Palie O, Michel P, Menard J, Rousseau C, Rio E, Bridji B, et al.
Eur J Nucl Med Mol Imaging
. 2013 May;
40(9):1345-55.
PMID: 23715903
Purpose: FDG PET has been suggested to have predictive value in the prognosis of oesophageal carcinoma. However, the retrospective studies reported in the literature have shown discordant results. Additionally, only...
10.
Gimenez-Roqueplo A, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, et al.
J Clin Endocrinol Metab
. 2012 Nov;
98(1):E162-73.
PMID: 23162105
Context: Recommendations have not been established concerning imaging to screen SDHx mutation carriers for paraganglioma and pheochromocytoma. Objective: Our objective was to compare the performance of gadolinium-enhanced magnetic resonance angiography,...